Medical News Today -
6 Nov 2013 12:00
Actelion (SIX: ATLN) has announced the commercial availability of OPSUMIT® (macitentan) 10mg, an oral, dual endothelin receptor antagonist (ERA) approved for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression. PAH is a chronic, life-threatening disorder that can severely compromise the function of the lungs and heart. The U.S. Food and Drug Administration (FDA) approved OPSUMIT on October 18, 2013. OPSUMIT® is indicated for the treatment of pulmonary arterial h...
Share this Article